Results 71 to 80 of about 4,251 (181)

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

, 2020
Background: Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients ...
Wierda W. G., Egyed M., Woyach J. A., Ghia P., Sharman J. P., Jurczak W., Byrd J. C., Karlsson K., Walewska R., Coutre S., Fogliatto L. M., Izumi R., Patel P., Cymbalista F., Wang M. H., Janssens A., Corbett G., Munugalavadla V., Herishanu Y., Walker P., Follows G., Skarbnik A., Flinn I. W., Munir T., Wong S., Pagel J. M., Kamdar M., Salles G., Banerji V.   +28 more
core   +2 more sources

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Patient Preference and Adherence, 2023
Xiaoxiao Lu,1 Bruno Emond,2 Laura Morrison,2 Frederic Kinkead,2 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2 Wasiulla Khan,1 Linda H Wu,1 Zaina P Qureshi,1 Ryan Jacobs3 1Real World Value and Evidence, Oncology, Janssen Scientific Affairs, LLC, Horsham, PA,
Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R   +9 more
doaj  

Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Varnimcabtagene autoleucel (var‐cel) is an autologous CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy administered using an adaptive, fractionated dosing strategy. We conducted a multicenter retrospective study to evaluate the safety and efficacy of var‐cel in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL ...
Nil Albiol, Nuria Martínez‐Cibrián, Amanda Isabel Pérez, Sergio Navarro‐Velázquez, Guilherme Muzzi, Aina Oliver‐Caldes, Marta Español‐Rego, Leticia Alserawan, Mercedes Montoro‐Lorite, Carla Ramos, Pilar Ayora, Ana África Martin‐López, Almudena Cabero, Estefanía Pérez‐López, Alejandro Martín García‐Sancho, Tycho Baumann, José María Sánchez‐Pina, Anabelle Chinea, Paula Fernández‐Caldas, Mariana Bastos‐Oreiro, Mi Kwon, Luis Gerardo Rodríguez‐Lobato, Laura Magnano, Andrea Rivero, Juan G. Correa, Pablo Mozas, María Sánchez‐Castañón, Juan J. Mata‐Molanes, Paola Charry, Jose R. Álamo, Xavier Setoaín, Sonia Rodríguez, Eulalia Olesti, Joaquín Sáez‐Peñataro, Carlos Fernández de Larrea, Álvaro Urbano‐Ispizua, Armando López‐Guillermo, Julio Delgado, E. Azucena González‐Navarro, Manel Juan, Eva Giné, Valentín Ortiz‐Maldonado   +41 more
wiley   +1 more source

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment

, 2022
Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
William Smith, Marbury, Thomas, Thomas Marbury, Vishwanathan, Karthick, Sharma, Shringi, Nguyen, Helen, Ware, Joseph A, Raquel Izumi, Xu, Yan, Smith, William, J. Greg Slatter, Kuo, Howard, Madere, Jeannine, Preston, Richard A., Slatter, J Greg, Yan Xu, Helen Nguyen, Anna Kwan, Kwan, Anna, Preston, Richard A, Podoll, Terry, Slatter, J. Greg, Jeannine Madere, Terry Podoll, Karthick Vishwanathan, Joseph A. Ware, Izumi, Raquel, Shringi Sharma, Ware, Joseph A., Howard Kuo, Richard A. Preston   +30 more
core   +1 more source

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network

Pharmacology Research & Perspectives
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults, characterized by the accumulation of dysfunctional lymphocytes. Ibrutinib, a first‐generation Bruton tyrosine kinase (BTK) inhibitor, has significantly improved CLL ...
Abdulrahman Majrashi, Ying X. Gue, Alena Shantsila, Stella Williams, Catrin Tudur Smith, Gregory Y. H. Lip, Andrew R. Pettitt   +6 more
doaj   +1 more source

Real‐World Treatment Patterns and Healthcare Resource Utilization of Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma in the United States

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The introduction of Bruton tyrosine kinase inhibitors (BTKis) to the mantle cell lymphoma (MCL) treatment paradigm has shown promising results for patient outcomes. However, insufficient real‐world evidence remains to compare the outcomes of different BTKi treatments in MCL.
Bijal Shah, Mei Xue, Wesley Furnback, Kaitlyn Esselman, Po‐Ya Chuang, Keri Yang   +5 more
wiley   +1 more source

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

, 2020
Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL).
Galimberti S., Al-Janazreh H., Martino M., Morabito F., Cutrona G., Recchia A. G., Abu-Rayyan M., Vigna E., Atrash M., Botta C., Skafi M., Gentile M., Morabito L.   +12 more
core   +1 more source

A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

, 2023
Video abstract for our matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic ...
Adam S. Kittai (15088179), Paolo Ghia (760385), Jack Roos (17101354), Alan Skarbnik (17101348), Sarah Palazuelos-Munoz (3578837), Miguel Miranda (1367058), Alan Yong (17101352), Robert Hettle (707560), Vikram Shetty (4810032)   +8 more
core   +1 more source

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma [PDF]

, 2019
Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity ...
Morschhauser, F. (Franck), Le-Gouill, S. (Steven), Morschhauser, F. (Frank), Frigault, M.M. (Melanie M.), Doorduijn, J.K. (Jeanette), Smith, S.D. (Stephen D.), Lamy, T. (Thierry), Kate, A.P. (Arnon P.), Panizo, C. (Carlos), Yin, M. (Ming), Dupuis, J. (Jehan), Damaj, G. (Gandhi), Shah, B. (Bijal), Oberic, L. (Lucie), Casasnovas, O. (O.), Doorduijn, J.K. (Jeanette K.), Rule, S. (Simon), Robak, T. (Tadeusz), Casasnovas, R. O. (René Olivier), Davies, A. (Andrew), Raquel, Wang, M. (Michael), Jain, P. (Preetesh), Jacobsen, E. (Eric), Izumi, R. (Raquel), Długosz-Danecka, M. (Monika), Patel, P (Priti), Goy, A. (Andre), Nguyen, D. (Dorothy), Dlugosz-Danecka, M. (Monika), Zinzani, P.L. (Pier Luigi), Patel, P. (Priti), Zinzani, P.L. (P. L.), Le Gouill, S. (Steven), Eek, R. (Richard), Kater, A.P. (Arnon)   +35 more
core   +1 more source

Comparison of BTK/acalabrutinib and BTK/tirabrutinib complexes.

, 2023
a. Superposition of the BTK KD/tirabrutinib structure solved here with the previously solved structure (PDB code: 5P9M) showing the different activation loop conformations as in Fig 2c. b.
Amy H. Andreotti (366314), David Y. Lin (16913868)   +1 more
core   +1 more source